Phase I/II Trial of Pembrolizumab and Androgen-receptor Pathway Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that increases the immune system's ability to destroy cancer cells). This study will assess whether 225Ac-J591 + pembrolizumab + androgen receptor pathway inhibitor (ARPI) is more effective against prostate cancer than pembrolizumab + ARPI alone.

Start Date12 Aug 2021

Sponsor / Collaborator

Weill Medical College of Cornell University

[+2]

NCT04886986

/ SuspendedPhase 1/2IIT

Phase I/II Study of 225Ac-J591 Plus 177Lu-PSMA-I&T for Progressive Metastatic Castration Resistant Prostate Cancer

This is a phase I/II dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA-I&T (also known as PNT2002). The two study drugs are 225Ac-J591 and 177Lu-PSMA-I&T. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates (radiation linked to antibodies/molecules that recognize prostate cancer cells). The first phase of the study (phase I) will determine the highest dose of the study drug that can be safely given. The second phase of the study (phase II) will determine the effectiveness of the drug combination in patients with prostate cancer.

Start Date30 Jun 2021

Sponsor / Collaborator

Weill Medical College of Cornell University

NCT04576871

/ Active, not recruitingEarly Phase 1IIT

Pilot Study of PSMA-TRT Re-treatment Utilizing 225Ac-J591

The purpose of this study is to find out if re-treatment with 225Ac-J591 can be given without severe side effects.

Start Date29 Oct 2020

Sponsor / Collaborator

Weill Medical College of Cornell University

100 Clinical Results associated with 225Ac-J591

100 Translational Medicine associated with 225Ac-J591

100 Patents (Medical) associated with 225Ac-J591

Literatures (Medical) associated with 225Ac-J591

03 Jun 2024·Clinical cancer research : an official journal of the American Association for Cancer Research

Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

Article

Author: Klotz, Monika ; Hammer, Stefanie ; Nielsen, Carsten H. ; Indrevoll, Bård ; Alfsen, Maria Z. ; Larsen, Åsmund ; Cuthbertson, Alan ; Schatz, Christoph A. ; Feng, Yuan Zeng ; Nair, Shankari ; Stargard, Stefan ; Bjerke, Roger M. ; Cruciani, Veronique ; Moen, Ingrid ; Hennekes, Hartwig ; Hagemann, Urs B. ; Zitzmann-Kolbe, Sabine ; Wickstrøm Biseth, Katrine ; Haendler, Bernard ; Karlsson, Jenny

Abstract:

Purpose::

Initially, prostate cancer responds to hormone therapy, but eventually resistance develops. Beta emitter-based prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy is approved for the treatment of metastatic castration-resistant prostate cancer. Here we introduce a targeted alpha therapy (TAT) consisting of the PSMA antibody pelgifatamab covalently linked to a macropa chelator and labeled with actinium-225 and compare its efficacy and tolerability with other TATs.

Experimental Design::

The in vitro characteristics and in vivo biodistribution, antitumor efficacy, and tolerability of 225Ac-macropa-pelgifatamab (225Ac-pelgi) and other TATs were investigated in cell line– and patient-derived prostate cancer xenograft models. The antitumor efficacy of 225Ac-pelgi was also investigated in combination with the androgen receptor inhibitor darolutamide.

Results::

Actinium-225-labeling of 225Ac-pelgi was efficient already at room temperature. Potent in vitro cytotoxicity was seen in PSMA-expressing (LNCaP, MDA-PCa-2b, and C4-2) but not in PSMA-negative (PC-3 and DU-145) cell lines. High tumor accumulation was seen for both 225Ac-pelgi and 225Ac-DOTA-pelgi in the MDA-PCa-2b xenograft model. In the C4-2 xenograft model, 225Ac-pelgi showed enhanced antitumor efficacy with a T/Cvolume (treatment/control) ratio of 0.10 compared with 225Ac-DOTA-pelgi, 225Ac-DOTA-J591, and 227Th-HOPO-pelgifatamab (227Th-pelgi; all at 300 kBq/kg) with T/Cvolume ratios of 0.37, 0.39, and 0.33, respectively. 225Ac-pelgi was less myelosuppressive than 227Th-pelgi. 225Ac-pelgi showed dose-dependent treatment efficacy in the patient-derived KuCaP-1 model and strong combination potential with darolutamide in both cell line– (22Rv1) and patient-derived (ST1273) xenograft models.

Conclusions::

These results provide a strong rationale to investigate 225Ac-pelgi in patients with prostate cancer. A clinical phase I study has been initiated (NCT06052306).

01 Mar 2024·JOURNAL OF CLINICAL ONCOLOGY

Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of ²²⁵Ac-J591

Article

Author: Vallabhajosula, Shankar ; Sternberg, Cora N. ; Nanus, David M. ; Ballman, Karla ; Bander, Neil H. ; Sartor, A. Oliver ; Stangl-Kremser, Judith ; Osborne, Joseph R. ; Sun, Michael ; Tagawa, Scott T. ; Molina, Ana ; Nauseef, Jones T. ; Castellanos, Sandra Huicochea ; Bissassar, Mahelia ; Thomas, Charlene

PURPOSE:

Novel therapies are needed to extend survival in metastatic castration-resistant prostate cancer (mCRPC). Prostate-specific membrane antigen (PSMA), a cell surface antigen overexpressed in PC, provides a validated target. This dose-escalation study investigated the safety, efficacy, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) for 225Ac-J591, anti-PSMA monoclonal antibody J591 radiolabeled with the alpha emitter actinium-225.

METHODS:

Following investigational new drug-enabling preclinical studies, we enrolled patients with progressive mCRPC that was refractory to or who refused standard treatment options (including androgen receptor pathway inhibitor and had received or been deemed ineligible for taxane chemotherapy). No selection for PSMA was performed. Patients received a single dose of 225Ac-J591 at one of seven dose-escalation levels followed by expansion at the highest dose. Primary end point of dose-escalation cohort was determination of dose-limiting toxicity (DLT) and RP2D.

RESULTS:

Radiochemistry and animal studies were favorable. Thirty-two patients received 225Ac-J591 in an accelerated dose-escalation design (22 in dose escalation, 10 in expansion). One patient (1 of 22; 4.5%) experienced DLT in cohort 6 (80 KBq/kg) but none in cohort 7; MTD was not reached, and RP2D was the highest dose level (93.3 KBq/kg). The majority of high-grade adverse events (AEs) were hematologic with an apparent relationship with administered radioactivity. Nonhematologic AEs were generally of low grade. Prostate-specific antigen (PSA) declines and circulating tumor cell (CTC) control were observed: 46.9% had at least 50% PSA decline at any time (34.4% confirmed PSA response), and protocol-defined CTC count response occurred in 13 of 22 (59.1%).

CONCLUSION:

To our knowledge, this is the first-in-human phase I dose-escalation trial of a single dose of 225Ac-J591 in 32 patients with pretreated progressive mCRPC demonstrated safety and preliminary efficacy signals. Further investigation is underway.

01 Oct 2023·The Prostate

Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.

Article

Author: Osborne, Joseph R ; Molina, Ana ; Bander, Neil H ; Nauseef, Jones T ; Sun, Michael ; Tagawa, Scott ; Thomas, Joseph ; Ho, Benedict ; Stangl-Kremser, Judith ; Nanus, David M ; Sternberg, Cora N

BACKGROUND:

Neutrophil count:lymphocyte count ratio (NLR) may be a prognostic factor for men with advanced prostate cancer. We hypothesized that it is associated with prostate-specific antigen (PSA) response and survival in men treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT).

METHODS:

Data of 180 men with metastatic castration-resistant prostate cancer (mCRPC) who were treated in sequential prospective radionuclide clinical trials from 2002 to 2021 (utilizing 177Lu-J591, 90Y-J591, 177Lu-PSMA-617, or 225Ac-J591) were retrospectively analyzed. We used a logistic regression to determine the association between NLR and ≥50% PSA decline (PSA50) and a Cox proportional hazards model to investigate the association between NLR and overall survival (OS).

RESULTS:

A total of 94 subjects (52.2%) received 177Lu-J591, 51 (28.3%) 177Lu-PSMA-617, 28 (15.6%) 225Ac-J591, and 7 (3.9%) 90Y-J591. The median NLR of 3.75 was used as cut-off (low vs. high NLR; n = 90, respectively). On univariate analysis, NLR was not associated with PSA50 (HR 1.08; 95% confidence interval [CI] 0.99-1.17, p = 0.067). However, it was associated with worse OS (hazard ratio [HR] 1.06, 95% CI 1.02-1.09, p = 0.002), also after controlling for circulating tumor cell count and cancer and leukemia group B risk group (HR 1.05; 95% CI 1.003-1.11, p = 0.036). Men with high NLR were at a higher hazard of death from all causes (HR 1.43, 95% CI 1.05-1.94, p = 0.024).

CONCLUSIONS:

NLR provides prognostic information in the setting of patients with mCRPC receiving treatment with PSMA-TRT.

News (Medical) associated with 225Ac-J591

10 Feb 2025

·www.prnewswire.com

Convergent Therapeutics Announces Two Clinical Trial Updates on CONV01-α at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2025

- Phase I Follow-Up Data Showed an Overall Survival of 29.8 Months with the Addition of CONV01-α to 177Lu-PSMA-I&T in Advanced Prostate Cancer CAMBRIDGE, Mass., Feb. 10, 2025 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced clinical trial updates for its lead asset, CONV01-α (225Ac-J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to actinium-225 (225Ac). Data will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which will take place February 13-15, 2025, in San Francisco, California. The first presentation, titled "Mature phase 1 follow up of alpha emitter 225Ac-J591 with 177Lu-PSMA-I&T in advanced prostate cancer," reported clinical follow-up of a Phase I dose-escalation trial exploring the addition of CONV01-α to 177Lu-PSMA-I&T, a PSMA-targeted beta emitting small molecule for the treatment of advanced prostate cancer. The study population presented included 18 patients (six at each dose level of CONV01-α) with progressive metastatic castration-resistant prostate cancer (mCRPC). Relatively low doses of CONV01-α were used. Data showed that the median overall survival was 29.8 months, with 10 patients still alive at the time of submission. Five patients were free from PSA progression at one year including one patient progression-free at 34 months on no active therapy. A decline in prostate-specific antigen (PSA) levels was seen in 94% of patients, 64% of patients achieved a PSA50 and 28% achieved a PSA90 response. Additionally, circulating tumor cell count changes were seen, with 80% of evaluable patients converting from "unfavorable" to "favorable." High grade adverse events were rare. "The impressive clinical activity is consistent with our pre-clinical data demonstrating that the antibody/ligand combination delivers a synergistic dose to tumor. Importantly, the synergistic tumor dose is achieved in the absence of additive toxicity due to the non-overlapping normal organ biodistribution of the ligand and antibody. This was also confirmed by the benign safety profile in the trial. The dosimetry and safety profile suggest the potential for additional cycles beyond the two cycles used in this trial. That the overall survival in this trial was double that of the Phase III VISION trial of 177Lu PSMA-617 further increases our enthusiasm for future trials of this combination," said Neil Bander, MD, Convergent's Co-Founder and Chief Scientific Officer and Professor Emeritus of Urology at Weill Cornell Medicine. The second presentation, titled "CONVERGE-01: Dosimetry, randomized dose optimization, dose escalation, and efficacy of Ac-225 rosopatamab tetraxetan in participants with PSMA-positive castration-resistant prostate cancer," is a "Trials in Progress" presentation of the three-part company sponsored Phase II trial evaluating the safety and efficacy of CONV01-α (225Ac-J591) monotherapy in patients with castration-resistant prostate cancer. Philip Kantoff, MD, Co-Founder and CEO said, "CONVERGE-01 is intended to confirm the high response rate and durability of CONV01-a monotherapy and solidify the path forward to our pivotal trial." About CONV01-α CONV01-α, Convergent's alpha-emitting radioantibody, combines the precision and pharmacokinetics of antibodies with the tumor-killing potential of alpha-emitting radionuclides. Specifically, CONV01-α uses a humanized monoclonal antibody targeted at prostate-specific membrane antigen (PSMA), which is highly overexpressed in prostate cancer cells. Since PSMA is a validated target, several therapeutics are directed at this antigen, and CONV01-α is differentiated by its use of both an antibody and alpha emitter. CONV01-α is linked to a powerful radionuclide called Ac-225, which releases alpha particles that kill cancer cells through DNA double-strand breaks. Unlike other radioactive sources, alpha particles deliver high-energy radiation over very short distances, thereby minimizing radiation exposure to healthy neighboring cells and tissues. Pairing highly selective antibodies with such a powerful, yet precise, payload offers the ideal combination to treat many types of cancers. Convergent Therapeutics is currently enrolling into the CONVERGE-01 Phase II monotherapy trial to confirm the high response rate, durability and safety of CONV01-a pre and post radioligand beta. About Convergent Therapeutics, Inc. Convergent Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing tumor-selective alpha radioantibodies to target cancer. The company was founded by world-renowned experts in clinical care and research, drug development, and cancer biology and its proprietary platform is licensed from Cornell University. In harnessing the selectivity of antibodies and tumor-destructive potential of alpha radioisotopes, Convergent's radioantibodies precisely target cancer cells with potent, localized radiation. For more information, please visit and follow us on X and LinkedIn. Media Relations: Bryan Blatstein Spectrum Science 917-714-2609 [email protected] SOURCE Convergent Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultASCOPhase 1Phase 2

02 Apr 2024

·www.prnewswire.com

Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen

- CONV01-α is an actinium-225 labeled radioantibody with proven efficacy and safety in multiple Phase 1/2 trials in prostate cancer patients - Convergent Therapeutics will conduct Phase 2 clinical trials in 2024 preparing for a registrational program in 2025 CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical stage biotechnology company focused on developing next generation radiopharmaceutical therapies for the treatment of prostate cancer and other cancers, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the investigational new drug ("IND") application for CONV01-α, its lead candidate for the treatment of patients with advanced prostate cancer. "Receiving clearance of our IND is a significant milestone for Convergent Therapeutics," said Convergent's Co-founder and CEO, Philip Kantoff, MD. "While we have already treated well over 100 prostate cancer patients in the context of investigator INDs, this new IND will allow us to rapidly advance CONV01-α into Phase 3 studies and expand the scope of clinical development of CONV01-α as a monotherapy and in combination with other cancer therapies." In a multi-dose, dose escalation study conducted in advanced prostate cancer patients, CONV01-α demonstrated a prostate-specific antigen decline of 50% (PSA50) in 67% of patients and a PSA decline of 90% (PSA90) in 27% of patients and was well tolerated.1 Ongoing studies suggest CONV01-α may be highly effective when used alone or in combination with other cancer therapies. "Importantly, patients also showed minimal side effects in Phase 1/2 trials. CONV01-α's ideal biodistribution delivers potent alpha particles while avoiding immediate and significant salivary gland toxicity as well as the potential delayed renal toxicity," said Neil Bander, MD, Convergent's Co-founder and CSO. "CONV01-α's design increases delivery of tumor-killing radiation to malignant cells while greatly reducing both off-tumor effects and the amount of radiation delivered per dose, thereby improving both treatment efficacy and safety." About CONV01-α CONV01-α, Convergent's alpha emitting radioantibody, combines the precision and pharmacokinetics of antibodies with the tumor-killing potential of alpha emitting radionuclides. Specifically, CONV01-α uses a humanized monoclonal antibody targeted at prostate-specific membrane antigen (PSMA) which is highly overexpressed in prostate cancer cells. Since PSMA is a validated target, several therapeutics are directed at this antigen and CONV01-α is differentiated by its use of both an antibody and alpha emitter. CONV01-α is linked to a powerful radionuclide called 225Ac, which releases alpha particles which kill cancer cells through DNA double strand breaks. Unlike other radioactive sources, alpha particles deliver high-energy radiation over very short distances, thereby minimizing radiation exposure to healthy neighboring cells and tissues. Pairing highly selective antibodies with such a powerful yet precise payload offers the ideal combination to treat many types of cancers. About Convergent Therapeutics, Inc. Convergent Therapeutics Inc. is a clinical-stage biotechnology company focused on developing tumor-selective alpha radioantibodies to target cancer. The company was founded by world-renowned experts in clinical care and research, drug development and cancer biology and its proprietary platform is licensed from Cornell University. In harnessing the selectivity of antibodies and tumor-destructive potential of alpha radioisotopes, Convergent's radioantibodies precisely target cancer cells with potent, localized radiation. For more information, please visit and follow us on Twitter and LinkedIn. 1Nauseef, J. T., et al. Abstract CT014: Phase I dose-escalation study of fractionated dose 225AC J591 for metastatic castration resistant prostate cancer. Cancer Research. 2023: 83(8_Supplement). SOURCE Convergent Therapeutics

Radiation TherapyIND

25 May 2023

·www.prnewswire.com

Convergent Therapeutics to Announce Clinical Trial Updates on its Lead Candidate at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

CAMBRIDGE, Mass., May 25, 2023 /PRNewswire/ -- Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the title of an upcoming poster presentation on its lead asset, CONV01-α (225Ac-J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to actinium-225 (225Ac) at the American Society of Clinical Oncology Annual Meeting, which is taking place in Chicago, June 2 – 6. The poster presentation entitled "Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T" will be presented by Dr. Scott Tagawa, Professor of Medicine and of Urology, member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and Attending Physician at NewYork-Presbyterian/Weill Cornell Medical Center. Details of the poster presentation are as follows: Abstract Title: Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T Presenter: Dr. Scott Tagawa*, Professor of Medicine and of Urology, member of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and Attending Physician at NewYork-Presbyterian/Weill Cornell Medical Center Date & Time: June 3, 1:15 pm CDT Location: E450 | On Demand Session Type: Poster Discussion Session Session Title: Genitourinary Cancer—Prostate, Testicular, and Penile Clinical Trial Registration Number: NCT04886986 Abstract number: 5018 Poster Bd number: 112 Dr. Tagawa is a paid consultant and equity stakeholder for Convergent Therapeutics and has been a paid consultant for POINT, Sanofi, Medivation, Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, Abbvie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, Blue Earth, Alkido Pharma, Telix Pharma, EMD Serono, Myovant, Merck, and Daiichi Sankyo. About Convergent Therapeutics, Inc. Convergent Therapeutics Inc. is a clinical-stage biotechnology company focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology was developed by Dr. Neil Bander, the Bernard and Josephine Chaus Professor of Urologic Oncology at Weill Cornell Medicine, and licensed to Convergent by Cornell University. CONV01-α, a monoclonal antibody conjugated to actinium-225 (Ac-225), a radioactive alpha particle emitter, was specifically designed to bind to the prostate-specific membrane antigen (PSMA). A key functional feature of CONV01-α is that once bound to PSMA, it becomes internalized, delivering its powerful radioactive payload directly into prostate cancer cells while minimizing damage to surrounding healthy tissue. CONV01-α has the potential to be the first Ac-225 radioantibody approved for use in prostate cancer treatment. For more information, please visit and follow us on Twitter and LinkedIn. Convergent Media Contact: Rob Haney, Ph.D. Russo Partners, LLC (401) 632-9316 [email protected] SOURCE Convergent Therapeutics

Phase 1ASCO

100 Deals associated with 225Ac-J591

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic castration-resistant prostate cancer	Phase 2	US	Weill Medical College of Cornell University	18 Aug 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04886986 (ASCO_GU2025)	Phase 1	Advanced Prostate Carcinoma PSMA PET \| SUVmax \| CTCs	18	225Ac-J591	ujoydnsfej(nfibrmuxpw) = wkyygaztfq qpuahgwnzu (nimsgaggro, 7.4 - NR) View more	Positive	13 Feb 2025
NCT04946370 (ESMO2024) Manual	Phase 1	Metastatic castration-resistant prostate cancer	12	Pembrolizumab 225Ac-J591	cjqvcopvqf(wnjailoywq) = determined to be 80 KBq/Kg txmxtafsgz (fpijbtjfva )	Positive	15 Sep 2024
NCT04946370 (ESMO2024) Manual	Phase 1	Metastatic castration-resistant prostate cancer	12	Pembrolizumab 225Ac-J591		Positive	15 Sep 2024
NCT04886986 (ASCO 12023 \| ASCO 22023) Manual	Phase 1/2	Prostatic Cancer	18	225Ac-J591+PNT2002	epmxgywvch(xjhvunozcc) = 2 of 6 pts with DLT at 40 KBq/Kg (Gr 2 or 3 thrombocytopenia delaying cycle 2 by >3 wk); no DLT observed in other cohorts. udelzzfird (yscrysayca ) View more	Positive	31 May 2023
AACR2023 Manual	Phase 1	Metastatic castration-resistant prostate cancer	24	225Ac J591	zkhhugfqvz(trvaaipylk) = No DLTs were observed in Cohort 1 (n=3) or 2 (n=6). In C3, 2/6 subjects experienced DLTs xmbpnpjfzd (thkwbqysjl ) View more	Positive	14 Apr 2023
NCT04946370 (ASCO_GU2023) Manual	Phase 1/2	Castration-Resistant Prostatic Cancer	13	pembrolizumab+225Ac-J591	dgesnugzig(gfzeirxivc) = 9 (75%) thrombocytopenia (3 with g≥3; 1 g4 with PC marrow infiltration), 7 (58%) neutropenia (none g≥3), 6 (50%) nausea, 7 (58%) g1-2 fatigue, 9 (75%) g1-2 xerostomia, 7 (58%) g1 AST rhrqxckzje (wmywmbowau ) View more	Positive	21 Feb 2023
NCT03276572 (Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591, CTgov)	Phase 1	Metastatic castration-resistant prostate cancer	32	225Ac-J591 (225Ac-J591 Cohort 1)	wfzmectabs(fauozqcxbo) = ooyfonjhyw ryvmtykump (rkrdmfhhzx, kmahwdfsnw - tpqyidbjnh) View more	-	06 Dec 2022
	Phase 1	Metastatic castration-resistant prostate cancer	32	225Ac-J591 (225Ac-J591 Cohort 2)	wfzmectabs(fauozqcxbo) = fplugcgwsv ryvmtykump (rkrdmfhhzx, yfuvscnwtd - hchcnwlfov) View more	-	06 Dec 2022
NCT04506567 (ASCO_GU2021)	Phase 1/2	Metastatic castration-resistant prostate cancer	-	225Ac-J591 (Fractionated-dose cohort)	gmbfxdmiyp(sqsljtcwxo) = lvwyyhprbq hrwpcnuayv (qofzkuezdq )	-	02 Mar 2021
NCT04506567 (ASCO_GU2021)	Phase 1/2	Metastatic castration-resistant prostate cancer	-	225Ac-J591 (Multiple-dose cohort)	gmbfxdmiyp(sqsljtcwxo) = fhiupndtfr hrwpcnuayv (qofzkuezdq )	-	02 Mar 2021
NCT03276572 (ASCO2020)	Phase 1	Metastatic castration-resistant prostate cancer	22	<sup>225</sup>Ac-J591	sanngnejxw(iyqvljnbrj) = hrdgutcjuj htxynkmyte (ksbhapyicg ) View more	Positive	25 May 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

225Ac-J591

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation